NERV
NASDAQMinerva Neurosciences Inc
News · 26 weeks53+900%
2026-03-012026-08-23
Mix2090d
- Insider10(50%)
- Other4(20%)
- SEC Filings4(20%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- INSIDERNew insider Reilly Joseph H. claimed ownership of 20,872 shares (SEC Form 3)3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERNew insider Aliquo Anthony claimed ownership of 1,683 shares (SEC Form 3)3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- ANALYSTMinerva Neurosciences upgraded by Jefferies with a new price targetJefferies upgraded Minerva Neurosciences from Hold to Buy and set a new price target of $10.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 8-K filed by Minerva Neurosciences Inc8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 10-Q filed by Minerva Neurosciences Inc10-Q - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences Provides Second Quarter 2026 Financial Results and Business UpdatesConfirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported financial and business updates for the second quarter ended June 30, 2026. "The psychiatry field has increasing
- INSIDERSEC Form 4 filed by Director Kaul Inderjit4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
- INSIDERSEC Form 4 filed by CEO Luthringer Remy4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Laghrissi-Thode Fouzia4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by SVP, CFO and Secretary Ahlholm Frederick W4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Kupfer David4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Hasler Hans Peter4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Van Heek G Jan4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaul Inderjit4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), fulfilling a commitment made in connection with the Company's PIPE financing announced on October 21, 2025. The SAB brings together distinguished researchers and clinicians with proven track records of advancing meaningful treatments in psychiatry and neuroscience. "The formation of this Scientific Advisory Board reflects our commitment to bringing the highest level of scientific rigor and clinical exp
- SECSEC Form 8-K filed by Minerva Neurosciences Inc8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 424B5 filed by Minerva Neurosciences Inc424B5 - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceBURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. 2026 Jefferies Global Healthcare ConferenceFormat:Fireside chatDay/Time:Thursday, June 4 at 4:20 PM ETWebcast:Link here If you are interested in meeting with the Minerva team during the conference, please reach out to your Jefferies representative. A replay of the presentat
- SECSEC Form SCHEDULE 13G filed by Minerva Neurosciences IncSCHEDULE 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
NERV FAQ
7 questionsWhat does Minerva Neurosciences Inc do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import...Where does NERV stock trade?
Minerva Neurosciences Inc (NERV) is listed on NASDAQ.What sector and industry is NERV in?
Minerva Neurosciences Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Minerva Neurosciences Inc go public?
Minerva Neurosciences Inc (NERV) completed its IPO in 2014.What are analysts saying about NERV?
Minerva Neurosciences Inc has had 3 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $1000.00 price target on 2026-08-14. Recent price targets range from $500.00 to $1400.00.What companies are similar to NERV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NERV side-by-side with any of them on Quantisnow.How can I track NERV on Quantisnow?
Quantisnow aggregates Minerva Neurosciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NERV to receive live email and push alerts on every new disclosure.